Reviews of "Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial"

Sandhya Vasan; Edward Mills

doi:doi:10.1162/2e3983f5.eb4d8f84

SearchLogin Login or Signup

Reviews of "Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial"

Reviewers: S Vasan (Henry M Jackson Foundation) | 📘📘📘📘📘 • E Mills (McMaster University) | 📘📘📘📘📘

by Sandhya Vasan and Edward Mills

Published onAug 15, 2022

1 of 2

This Pub is a Review of

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

by Susanna Naggie and Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group

dx.doi.org

To read the original manuscript, click the link above.

Summary of Reviews: This preprint evaluated the effectiveness of ivermectin in shortening symptom duration or preventing hospitalization in people with mild-moderate COVID-19 symptoms. Both reviewers are in agreement that this study provides strong support for its claim that ivermectin does not seem to provide any clinically significant improvement in treatment outcomes.

Reviewer 1 (Sandhya V) | 📘📘📘📘📘

Reviewer 2 (Edward M) | 📘📘📘📘📘

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below.

Connections

1 of 2

A Supplement to this Pub

Review 1: "Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial"

by Sandhya Vasan

Show Description
Published on Aug 15, 2022
rrid.mitpress.mit.edu

Description

Both reviewers are in agreement that this study provides strong support for its claim that ivermectin does not seem to provide any clinically significant improvement in treatment outcomes.

A Supplement to this Pub

Review 2: "Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial"

by Edward Mills

Show Description
Published on Aug 15, 2022
rrid.mitpress.mit.edu

Description

Both reviewers are in agreement that this study provides strong support for its claim that ivermectin does not seem to provide any clinically significant improvement in treatment outcomes.

License

Creative Commons Attribution 4.0 International License (CC-BY 4.0)

Comments

Jacintha Kyomi:

I appreciate your article as well as your research. However, it is a fact that we cannot completely eliminate Covid from human life. Therefore, preventive measures are extremely necessary and effective. For example, disinfecting hands, wearing masks when going out and staying at home to play donkey kong to prevent the spread of disease.